Hirano currently serves as the Amgen Endowed Chair in Cancer Research at Princess Margaret Cancer Centre, University Health Network. In addition, he holds the positions of Chair of the Immuno-Oncology Program, Associate Director for Research in the Tumor Immunotherapy Program, and Senior Scientist at the same center. Hirano also contributes as a Professor in the Department of Immunology at the University of Toronto, a Senior Investigator at the Ontario Institute for Cancer Research, and Co-founder of TCRyption Inc., a company that specialises in T cell-based immunotherapies. Dr. Hirano focuses on developing new antitumor immunotherapies, aiming to bridge research and clinical application in cancer treatment.